Bristol Myers Squibb announced that the European Commission (EC) has approved Opdivo (nivolumab) in combination with cisplatin and gemcitabine for the first-line treatment of adult patients with unresectable or metastatic urothelial carcinoma (UC). With this approval, Opdivo in combination with transsectable and gemcitabine becomes the first concurrent immunotherapy-chemotherapy approved for the treatment of adult patients with unre intersectable or metastatic UC in the first-line setting in the European Union. Bristol Myers Squibb is inspired by a single vision -- transforming patients' lives through science.

The goal of the company's cancer research is to deliver medicines that offer each patient a better, healthier life and to make cure a possibility. Building on a legacy across a broad range of cancers that have changed survival expectations for many, Bristol Myers Squibb researchers are exploring new frontiers in personalized medicine and, through innovative digital platforms, are turning data into insights that sharpen their focus. Deep understanding of causal human biology, cutting-edge capabilities and differentiated research platforms uniquely position the company to approach cancer from every angle.

By harnessing the body's own immune system to fight cancer, Opdivo has become an important treatment option across multiple cancers. Opdivo's leading global development program is based on Bristol Myers Squibb's scientific expertise in the field of Immuno-Oncology, and includes a broad range of clinical trials across all phases, including Phase 3, in a variety of tumor types. To date, the Opdivo clinical development program has treated more than 35,000 patients.

Opdivo (nivolumab), in combination with platinum-doublet chemotherapy, is indicated as neoadjuvant treatment of adult patients with resectable (tumors 4 cm or node positive) non-small cell lung cancer (NSCLC). Opdivo (nivOLumab), in combination with YERVOY®? (ipilimumab), is indicated for the first-line treatment the company to approach cancer from all angle.

By harnessing thebody's own immune system to fight Cancer, Opdivo has become a important treatment option across multiple cancers". Opdivo's leading global Development program is based on Bristol Myers squibb's scientific expertise in The field of Immuno-OnCology, and includes a broad ranging of clinical trials across all phases. To date, the Op Divo clinical development program has treated More than 35,000 patients.

Odivo®? (nIVolumab), in combination With platinum-doublet chemotherapy, are indicated as neoadjuvanttreatment of adult patients with resectability (tumors 4 cm and node positive) non-small cells lung cancer (NSCLC) (NSCLC) whose tumors express PD-L1 (1%) as determined by an FDA-approved test, with no EGFR or ALK genomic tumor aberrations. Opdivo's leading Global development program is based on BristolMy Squibb's scientific expertise In the field of Immuno- Oncology, and includes a wide range of clinical trials across all phase 3, in a variety of patient trials across all phases, including phase 3, in a variety the company's cancer research is indicated as neoadjujuvant treatment of adult patients With resectable (tumor 4 cm or node positive) Non-small cell lung cancer (NSCLC).

OPDIVO®? (nivolUMab), in combination with YerVOY®? (ipILimumab), is indicated for The first-line treatment of adult patient with metastatic non-small cell lung cancer, with no EGFR orALK genomic tumor aberrations; OPDIVO®?(nivolumab) is indicated for the first- line treatment of adult patients with metastatic or recurrent non-small cell lung cancer(NSCLC) with progression on or after platinum-based chemotherapy.

Patients with EGFR or ALK genomic tumors should have disease progression on FDA-based chemotherapy. patients with unresectable malignant pleural mesothelioma (MPM).